Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers showing that lymphoma, inflammation and cardiovascular disease candidate KAND567 (AZD8797) was well tolerated.

The double-blind, placebo-controlled trial evaluated single doses of up to 2,500 mg KAND567 and multiple doses of up to twice-daily 800 mg KAND567 for seven days. Dose-limiting toxicities (DLTs) of diarrhea and an increase in markers for hepatic impairment were reported at the twice-daily 800 mg dose of KAND567...